Stoke Therapeutics Unveils Two-Year ADOA Study Data at AAO Meeting
Reuters
Oct 20, 2025
Stoke <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Two-Year ADOA Study Data at AAO Meeting
Stoke Therapeutics Inc. has announced the presentation of two-year natural history data from the FALCON study, which evaluated patients with Autosomal Dominant Optic Atrophy (ADOA). The results were presented at the 2025 American Academy of Ophthalmology (AAO) Annual Meeting. The FALCON study is the largest prospective natural history study of ADOA, a rare genetic disease that leads to progressive vision loss. Findings indicate that no significant anatomic changes in the retina were observed over two years, suggesting that retinal dysfunction may be reversible with treatment. These data have informed Stoke Therapeutics' ongoing clinical development of STK-002, a proprietary antisense oligonucleotide currently being evaluated in the Phase 1 OSPREY study as a potential disease-modifying therapy for ADOA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251020363125) on October 20, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.